A spotlight group of supportive care well being professionals and shoppers mentioned issues about how the pandemic has modified care of sufferers with genitourinary (GU) cancers. Themes from the dialogue have been printed within the Asia-Pacific Journal of Medical Oncology.
The purpose of the main target group was to know how the COVID-19 pandemic has affected healthcare supply and medical trials within the setting of GU cancers. Seventy-two contributors have been recruited previous to a convention workshop hosted by the Australian New Zealand Urogenital and Prostate Most cancers Trials Group for supportive care well being professionals in November 2020.
The main focus group comprised shoppers, nurses, and medical psychologists.
Proceed Studying
The shoppers said that the COVID-19 pandemic affected their capability to journey to GU most cancers care appointments as a consequence of fears of utilizing public transportation and altering their mode of transport affected their out-of-pocket bills. On the whole, the sufferers transitioned to telehealth appointments the place attainable and opted to have drugs delivered on to their house.
Nurses described their expertise utilizing phone or video consultations to handle affected person wants. They said that delays in appointments tended to happen extra when COVID-19 instances have been greater, and the nurses have been involved that ongoing delays may have long-term results on remedy and outcomes.
As well as, nurses said that speedy coverage modifications, reminiscent of a shift to outpatient testing and evaluation, and restricted collaboration with medical groups could have affected the standard of look after some sufferers.
Nurses additionally expressed issues with affected person assist, wherein members of the family could have been barred from attending in-person appointments or from visiting a affected person throughout their end-of-life care.
“Embedding improvements reminiscent of telehealth and teletrials into normal care and streamlining medical trial processes would require modifications in coverage, follow, schooling, and analysis,” the research authors concluded. “Whereas change continues, there may be an excessive amount of work required to make sure modifications are evaluated and applied in an evidence-based means.”
Reference
Roberts NA, Dhillon HM, Paterson C, Schubach Okay, McJannett M; Australian and New Zealand Urogenital and Prostate Most cancers Trials Group. The affect of coronavirus illness 2019 on genitourinary and prostate most cancers care and medical trials: A qualitative exploration of the Australian and New Zealand expertise. Asia Pac J Clin Oncol. Revealed on-line October 25, 2022. doi:10.1111/ajco.13847
This text initially appeared on Oncology Nurse Advisor
